Since the acquisition, AbbVie has used Allergan’s aesthetics and neuroscience portfolios to diversify its revenue.
: The Allergan division, now branded as Allergan Aesthetics , continues to lead the global medical aesthetics market with products like Botox. allergan stock buy or sell
: For the full year 2026, management has guided for net revenues of approximately $67 billion, representing 9.5% growth. Historical Acquisition Terms Since the acquisition
: Analysts are currently focused on AbbVie's ability to offset the loss of exclusivity for its flagship drug, Humira, through newer immunology drugs like Skyrizi and Rinvoq . now branded as Allergan Aesthetics